Analyst Estimates: Here's What Brokers Think Of KORU Medical Systems, Inc. (NASDAQ:KRMD) After Its Third-Quarter Report
The investors in KORU Medical Systems, Inc.'s (NASDAQ:KRMD) will be rubbing their hands together with glee today, after the share price leapt 22% to US$3.69 in the week following its quarterly results. Results were overall in line with expectations, with the company breaking even at the statutory earnings per share (EPS) level on US$12m in revenue. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on KORU Medical Systems after the latest results.
After the latest results, the four analysts covering KORU Medical Systems are now predicting revenues of US$56.0m in 2027. If met, this would reflect a substantial 21% improvement in revenue compared to the last 12 months. KORU Medical Systems is also expected to turn profitable, with statutory earnings of US$0.017 per share. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$56.3m and earnings per share (EPS) of US$0.02 in 2027. So there's definitely been a decline in sentiment after the latest results, noting the real cut to new EPS forecasts.
Check out our latest analysis for KORU Medical Systems
The consensus price target held steady at US$6.13, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on KORU Medical Systems, with the most bullish analyst valuing it at US$8.00 and the most bearish at US$4.50 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 16% growth on an annualised basis. That is in line with its 14% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 7.5% annually. So although KORU Medical Systems is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.
The Bottom Line
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for KORU Medical Systems. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at US$6.13, with the latest estimates not enough to have an impact on their price targets.
With that in mind, we wouldn't be too quick to come to a conclusion on KORU Medical Systems. Long-term earnings power is much more important than next year's profits. We have forecasts for KORU Medical Systems going out to 2028, and you can see them free on our platform here.
We also provide an overview of the KORU Medical Systems Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.